Drug Profile
Oxyntomodulin long-acting - OPKO Health
Alternative Names: MOD-6031Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator PROLOR Biotech
- Developer OPKO Health
- Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in Israel (SC, Injection)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Obesity in Israel (SC, Injection)
- 03 Mar 2016 Preclinical trials in Diabetes mellitus in Israel (SC) before March 2016